Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.
Anne M A TryggestadKarol AxcronaUlrika AxcronaIris BigalkeBjørn BrennhovdElse Marit InderbergTurid K HønnåshagenLisbeth J SkogeGuri SolumStein Saebøe-LarssenDag JosefsenRichard W OlaussenSteinar AamdalRolf I SkotheimTor-Åge MyklebustDolores J SchendelWolfgang A LillebySvein DuelandGunnar KvalheimPublished in: The Prostate (2021)
Patients diagnosed with EPE and ISUP grade 5 PC were at particularly high risk of developing postsurgical BCR. In this subgroup, the vaccine response was related to a reduced BCR incidence. The vaccine was safe, without side effects. This adjuvant first-in-man Phase I/II DC vaccine study showed promising results. DC vaccines after curative surgery should be investigated further in a larger cohort of patients with high-risk PC.
Keyphrases
- prostate cancer
- radical prostatectomy
- dendritic cells
- acute lymphoblastic leukemia
- early stage
- end stage renal disease
- minimally invasive
- ejection fraction
- newly diagnosed
- randomized controlled trial
- rectal cancer
- peritoneal dialysis
- risk factors
- clinical trial
- coronary artery bypass
- regulatory t cells
- patient reported outcomes
- atomic force microscopy
- high speed